反应停抗肿瘤作用研究进展

Advances in anti-tumor effect of thalidomide

肿瘤的生长有赖于血管生成,血管生成是肿瘤侵袭、转移的基础。抑制血管生成可使肿瘤萎缩坏死或使微转移灶长期处于“休眠”状态。反应停于上世纪中叶作为非巴比妥类镇静剂用于早孕反应,后曾因严重的致畸作用而被禁用。近年研究发现,反应停能明显抑制兔角膜血管生成,具有血管生成抑制作用,因而被应用于肿瘤研究。然而,实验研究中反应停对实体瘤的抗肿瘤效应并不一致,作用机制也未完全明了。我们对反应停药理作用、抗肿瘤效用、作用机制及临床应用等方面的研究进展予以综述。

Malignant tumor's growth, invasion and metastasis depend on the process of angiogenesis. Obliteration of the feeding vessels to a tumor could cause its shrinkage or death or keep the micro metastases in “hibernation” state for long term. It is found in recent research that thalidomide, which was used as a non-barbital sedative on nausea of morning sickness in pregnant women in the 1950s and then removed from markets for its severe side effects of teratognesis, has the effect of antiangiogenesis and is employed in tumor research. However, in current studies on its anti-tumor effects are not assent and the mechanisms in which is also need to declare. Advances in the respects of its pharmacodynamics, anti-tumor effects, machanisms and clinical studies are reviewed in this paper.